Dr. Christopher G. Cann, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 101
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Temple University School of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license MD481183 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Temple University Hospital Philadelphia, PA
Medical groups
- Temple Faculty Practice Plan Inc (1,368 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 101
- Services billed
- 308
- Patients’ average age
- 72
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 13 payments worth $3,438 in total to this clinician.
| Taiho Oncology, Inc. | $2,264 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $659 |
| AstraZeneca Pharmaceuticals LP | $291 |
| Eisai Inc. | $106 |
| Gilead Sciences, Inc. | $37.78 |
| Ipsen Biopharmaceuticals, Inc | $24.77 |
| Beone Medicines USA, Inc. | $24.39 |
| GlaxoSmithKline, LLC. | $16.47 |
| Consulting Fee | $2,759 |
|---|---|
| Food and Beverage | $679 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Taiho Oncology, Inc. Jun 9, 2025 | Consulting Fee LONSURF · Oncology | $2,100 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee | $659 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $83,989 in research payments for these studies, mostly to the institutions running them.
- A phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or g…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.